Effects of commonly used topical antimicrobial agents on Acinetobacter baumannii: An in vitro study

Military Medicine

Volumn 173, Issue 1, 2008, Pages 74-78

  Davis, Stephen C ^a   Pisanni, Franco ^a   Montero, Ramon B ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BACITRACIN PLUS NEOMYCIN PLUS POLYMYXIN; BACITRACIN PLUS POLYMYXIN; MAFENIDE; MAFENIDE ACETATE; NEOSPORIN; POLYSPORIN; PSEUDOMONIC ACID; SULFADIAZINE SILVER; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BATTLE INJURY; CREAM; DEATH; DRUG EFFECT; HUMAN; IN VITRO STUDY; INFECTION PREVENTION; IRAQ; NONHUMAN; SEPTICEMIA; SOLDIER; WOUND DRESSING; WOUND INFECTION;

EID: 38149107324     PISSN: 00264075     EISSN: None     Source Type: Journal    
DOI: 10.7205/MILMED.173.1.74     Document Type: Article

References (46)

1. Graevenitz A: Acinetobacter, Alcaligenes, Moraxella, and other nonfermentative Gram-negative bacteria. In: Manual of Clinical Microbiology, Ed 6, pp 520-32. Edited by Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH. Washington, DC, American Society for Microbiology, 1995.
2. Jawad A, Seifert H, Snelling AM, Heritage J, Hawkey PM: Survival of Acinetobacter baumannii on dry surfaces: comparison of outbreak and sporadic isolates. J Clin Microbiol 1998; 36: 1938-41.
3. Berlau J, Aucken H, Malnick H, Pitt T: Distribution of Acinetobacter species on skin of healthy humans. Eur J Clin Microbiol Infect Dis 1999; 18: 179-83.
4. Scott PT, Petersen K, Fishbain J, et al: Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002-2004. MMWR 2004; 53: 1063-6.
5. Whitman TJ. Infection control challenged related to war infections in the ICU setting. J Trauma 2007; 62: S53.
6. Tong MJ: Septic complications of war wounds. JAMA 1972; 219: 1044-7.
7. Griffith ME, Lazarus DR, Mann PB, Boger JA, Hospenthal DR, Murray CK: Acinetobacter skin carriage among U.S. Army soldiers deployed in Iraq. Infect Control Hosp Epidemiol 2007; 28: 720-2.
8. Scott P, Deye G, Srinivansan A, et al: An outbreak of multidrug-resistant Acinetobacter baumannii-calcoaceticus complex infection in the U.S. military health care system associated with military operations in Iraq. Clin Infect Dis 2007; 44: 1577-84.
9. Wang SH, Sheng WH, Chang YY, et al: Healthcare-associated outbreak due to pan-drug resistant Acinetobacter baumannii in a surgical intensive care unit. J Hosp Infect 2003; 53: 97-102.
10. Wei LH, Zhang J, Deng JJ, et al: The isolation of Acinetobacter strain from burn wound and the analysis of its antibiotic resistance [in Chinese].. Zhonghua Shao Shang Za Zhi 2004; 20: 17-9.
11. Green AR, Milling MAP: Infection with Acinetobacter in a burns unit. Burns 1983; 9: 292-4.
12. Chiang WC, Su CP, Hsu CY, et al: Community-acquired bacteremic cellulitis caused by Acinetobacter baumannii. J Formos Med Assoc 2003; 102: 650-2.
13. Allen DM, Hartman BJ: Acinetobacter species. In: Principles and Practices of Infectious Diseases, pp 2009-13. Edited by Mandell GL, Douglas RG, Bennett JE. New York, Churchill Livingstone, 1995.
14. Seifert H, Baginski R, Schulze A, Pulverer G: The distribution of Acinetobacter species in clinical culture materials. Int J Med Microbiol Virol Parasitol Infect Dis 1993; 279: 544-52.
15. Nathan P, Law EJ, Murphy DF, et al: A laboratory method for selection of topical antimicrobial agents to treat infected burn wounds. Burns 1978; 4: 177-87.
16. Barret JP, Heggers JP: Wound care. In: A Color Atlas of Total Burn Care, Ed 1, pp 70-81. Edited by Herndon DN, Barret JP. London, U.K., Bailliere Tindall, 2000.
17. Jones SA, Bowler PG, Walker M, Parsons D: Controlling wound bioburden with a novel silver-containing Hydrofiber dressing. Wound Repair Regen 2004; 12: 288-94.
18. Cisneros JM, Rodriguez-Bano J: Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment. Clin Microbiol Infect 2002; 8: 687-93.
19. Seifert H, Strate A, Pulverer G: Nosocomial bacteremia due to Acinetobacter baumannii: clinical features, epidemiology, and predictors of mortality. Medicine 1995; 74: 340-9.
20. Tilley PA, Roberts FJ: Bacteremia with Acinetobacter species: risk factors and prognosis in different clinical settings. Clin Infect Dis 1994; 18: 896-900.
21. Cisneros JM, Reyes MJ, Pachon J, et al: BSI due to Acinetobacter baumannii: epidemiology, clinical findings and prognostic features. Clin Infect Dis 1996; 22: 1026-32.
22. Lin SY, Wong WW, Fung CP, Liu CE, Liu CY: Acinetobacter calcoaceticus-baumannii complex bacteremia: analysis of 82 cases. J Microbiol Immunol Infect 1998; 31: 119-24.
23. Fass RJ, Barnishan J, Solomon MC, et al: In vitro activities of quinolones, β-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative Gram-negative bacilli. Antimicrob Agents Chemother 1996; 40: 1412-8.
24. Ling JM, Ng TKC, Cheng AF, et al: Susceptibilities to 23 antimicrobial agents and β-lactamase production of blood culture isolates of Acinetobacter species in Hong Kong. Scand J Infect Dis 1996; 101: 21-5.
25. Jain R, Danziger LH: Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann Pharmacother 2004; 38: 1449-59.
26. Wang FD, Lin ML, Lee WS, Liu CY: In vitro activities of β-lactam antibiotics alone and in combination with sulbactam against Gram-negative bacteria. Int J Antimicrob Agents 2004; 23: 590-5.
27. Bergogne-Berezin E, Towner KJ: Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996; 9: 148-65.
28. Cesur S: Topical antibiotics and clinical use [in Turkish]. Mikrobiyol Bul 2002; 36: 353-61.
29. Spann CT, Taylor SC, Weinberg JM: Topical antimicrobial agents in dermatology. Dis Mon 2004; 50: 407-21.
30. Daroczy J: Quality control in chronic wound management: the role of local povidone-iodine (Betadine) therapy. Dermatology 2006; 212(Suppl 1): 82-7.
31. Davis SC, Martinez L, Kirsner R: The diabetic foot: the importance of biofilms and wound bed preparation. Curr Diab Rep 2006; 6: 439-45.
32. Vu H, McCoy LF, Carino E, et al: Burn wound infection susceptibilities to topical agents: the Nathan's agar well diffusion technique. P&T 2002; 27: 390-6.
33. Rhody C: Bacterial infections of the skin. Prim Care 2000; 27: 459-73.
34. Hamilton-Miller JM, Shah S, Smith C: Silver sulphadiazine: a comprehensive in vitro reassessment. Chemotherapy 1993; 39: 405-9.
35. Deshpande LM, Chopade BA: Plasmid mediated silver resistance in Acinetobacter baumannii. Biometals 1994; 7: 49-56.
36. Shakibaie MR, Kapadnis BP, Dhakephalker P, et al: Removal of silver from photographic wastewater effluent using Acinetobacter baumannii BL54. Can J Microbiol 1999; 45: 995-1000.
37. Craig AW, Reboli A: Infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. J Infect Dis 1993; 168: 1602-3.
38. Fernandez-Viladrich P, Corbella X, Corral L, et al: Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium. Clin Infect Dis 1999; 28: 916-7.
39. Reis AO, Luz DA, Tognim MC, et al: Polymyxin-resistant Acinetobacter spp. isolates: what is next? Emerg Infect Dis 2003; 9: 1025-7.
40. Borisova OK, Makarenkova RV, Bogatova IS, Kutsidi EV: Antibiotic sensitivity of Acinetobacter calcoaceticus in patients with infected burns [in Russian]. Antibiotiki 1982; 27; 447-50.
41. Gonzalez G, Ramirez C, Munoz M: Antibacterial activity of aminoglycosides against nosocomial strains of Acinetobacter baumannii isolated between 1990 and 1999 [in Spanish]. Rev Esp Quimioter 2000; 13: 401-4.
42. Lam PK, Chan ES, Ho WS, Liew CT: In vitro cytotoxicity testing of a nanocrystalline silver dressing (Acticoat) on cultured keratinocytes. Br J Biomed Sci 2004; 61: 125-7.
43. Dunn K, Edwards-Jones V: The role of Acticoat with nanocrystalline silver in the management of burns. Burns 2004; 30(Suppl 1): S1-9.
44. Brown TP, Cancio LC, McManus AT, Mason AD Jr: Survival benefit conferred by topical antimicrobial preparations in burn patients: a historical perspective. J Trauma 2004; 56: 863-6.
45. Davis SC, Bouzari N: Development of antimicrobials for wound care: in-vitro and in-vivo assessments. Wounds 2004; 16: 344-7.
46. Davis SC, Cazzaniga AL, Eaglstein WH, Mertz PM: Over-the-counter topical antimicrobials: effective treatments? Arch Dermatol Res 2005; 297: 190-5.